investor.alimerasciences.com investor.alimerasciences.com

investor.alimerasciences.com

Investor Relations | Alimera Sciences

Skip to main navigation. Diabetic Macular Edema (DME). Retinal Vein Occlusion (RVO). Age-Related Macular Degeneration (AMD). Alimera Sciences’ primary focus is on ILUVIEN. Fluocinolone acetonide intravitreal implant) 0.19 mg. ILUVIEN is an intravitreal implant of fluocinolone acetonide and is the first DME treatment to deliver 36 months of continuous, low-dose corticosteroid therapy with a single injection. Feb 28, 2018. Alimera Sciences Reports Fourth Quarter and Full Year 2017 Financial Results. 2018 A...

http://investor.alimerasciences.com/

WEBSITE DETAILS
SEO
PAGES
SIMILAR SITES

TRAFFIC RANK FOR INVESTOR.ALIMERASCIENCES.COM

TODAY'S RATING

>1,000,000

TRAFFIC RANK - AVERAGE PER MONTH

BEST MONTH

October

AVERAGE PER DAY Of THE WEEK

HIGHEST TRAFFIC ON

Wednesday

TRAFFIC BY CITY

CUSTOMER REVIEWS

Average Rating: 4.3 out of 5 with 16 reviews
5 star
7
4 star
6
3 star
3
2 star
0
1 star
0

Hey there! Start your review of investor.alimerasciences.com

AVERAGE USER RATING

Write a Review

WEBSITE PREVIEW

Desktop Preview Tablet Preview Mobile Preview

LOAD TIME

0.2 seconds

FAVICON PREVIEW

  • investor.alimerasciences.com

    16x16

CONTACTS AT INVESTOR.ALIMERASCIENCES.COM

Login

TO VIEW CONTACTS

Remove Contacts

FOR PRIVACY ISSUES

CONTENT

SCORE

6.2

PAGE TITLE
Investor Relations | Alimera Sciences | investor.alimerasciences.com Reviews
<META>
DESCRIPTION
Skip to main navigation. Diabetic Macular Edema (DME). Retinal Vein Occlusion (RVO). Age-Related Macular Degeneration (AMD). Alimera Sciences’ primary focus is on ILUVIEN. Fluocinolone acetonide intravitreal implant) 0.19 mg. ILUVIEN is an intravitreal implant of fluocinolone acetonide and is the first DME treatment to deliver 36 months of continuous, low-dose corticosteroid therapy with a single injection. Feb 28, 2018. Alimera Sciences Reports Fourth Quarter and Full Year 2017 Financial Results. 2018 A...
<META>
KEYWORDS
1 alimera sciences
2 areas of focus
3 diabetic retinopathy
4 products overview
5 iluvien for dme
6 nadph oxidase inhibitors
7 full prescribing information
8 iluvien patent notices
9 investor relations
10 investor overview
CONTENT
Page content here
KEYWORDS ON
PAGE
alimera sciences,areas of focus,diabetic retinopathy,products overview,iluvien for dme,nadph oxidase inhibitors,full prescribing information,iluvien patent notices,investor relations,investor overview,events and presentation,corporate governance,news
SERVER
nginx
CONTENT-TYPE
utf-8
GOOGLE PREVIEW

Investor Relations | Alimera Sciences | investor.alimerasciences.com Reviews

https://investor.alimerasciences.com

Skip to main navigation. Diabetic Macular Edema (DME). Retinal Vein Occlusion (RVO). Age-Related Macular Degeneration (AMD). Alimera Sciences’ primary focus is on ILUVIEN. Fluocinolone acetonide intravitreal implant) 0.19 mg. ILUVIEN is an intravitreal implant of fluocinolone acetonide and is the first DME treatment to deliver 36 months of continuous, low-dose corticosteroid therapy with a single injection. Feb 28, 2018. Alimera Sciences Reports Fourth Quarter and Full Year 2017 Financial Results. 2018 A...

INTERNAL PAGES

investor.alimerasciences.com investor.alimerasciences.com
1

Events & Presentations | Alimera Sciences, Inc.

http://investor.alimerasciences.com/events.cfm

Diabetic Macular Edema (DME). Retinal Vein Occlusion (RVO). Age-Related Macular Degeneration (AMD). Details on upcoming events are not yet available. Aug 4, 2016. 2Q 2016 Earnings Conference Call. Jul 12, 2016. Alimera Sciences Presentation at the Cantor Fitzgerald Conference. Jun 8, 2016. Alimera Sciences Presentation at the LD Micro Invitational Conference. May 23, 2016. Alimera Sciences Presentation at UBS Global Healthcare Conference. May 5, 2016. 1Q 2016 Earnings Conference Call. Mar 9, 2016.

2

Corporate Governance | Alimera Sciences, Inc.

http://investor.alimerasciences.com/governance.cfm

Diabetic Macular Edema (DME). Retinal Vein Occlusion (RVO). Age-Related Macular Degeneration (AMD). Also included in the materials below are other important information about Alimera related to Alimera, including Alimera’s Securities Trading Policy and Foreign Corrupt Practices Act Policy. The materials are subject to modification from time to time as the Board of Directors deems appropriate in the best interests of Alimera or as required by applicable laws and regulations. Code of Business Conduct.

3

Financial Information | Alimera Sciences, Inc.

http://investor.alimerasciences.com/financials.cfm

Diabetic Macular Edema (DME). Retinal Vein Occlusion (RVO). Age-Related Macular Degeneration (AMD). Here you will find a summary of Alimera Sciences, Inc.'s latest financial information. Latest Earnings Release and 10-Q. Second Quarter Financial Results. Aug 5, 2016. May 6, 2016. Mar 15, 2016. Apr 27, 2016. Apr 27, 2016. Add PDF file to Briefcase. Aug 19, 2016. Quotes delayed at least 20 min., by eSignal. 2016 Alimera Sciences. This site intended for US residents only. US-UNB-MMM-0001.

4

Stock Information | Alimera Sciences, Inc.

http://investor.alimerasciences.com/stockquote.cfm

Diabetic Macular Edema (DME). Retinal Vein Occlusion (RVO). Age-Related Macular Degeneration (AMD). Alimera Sciences, Inc. (NASDAQ: ALIM). 10:23 AM ET on Aug 19, 2016. Sign up for email alerts. 2016 Alimera Sciences. This site intended for US residents only. US-UNB-MMM-0001.

5

Investor Overview | Alimera Sciences, Inc.

http://investor.alimerasciences.com/index.cfm

Diabetic Macular Edema (DME). Retinal Vein Occlusion (RVO). Age-Related Macular Degeneration (AMD). Alimera Sciences’ primary focus is on ILUVIEN. Fluocinolone acetonide intravitreal implant) 0.19 mg. ILUVIEN is an intravitreal implant of fluocinolone acetonide and is the first DME treatment to deliver 36 months of continuous, low-dose corticosteroid therapy with a single injection. View all ». Aug 16, 2016. Aug 11, 2016. Alimera Sciences Prices Public Offering of Common Stock. Aug 19, 2016. 2016 Alimera...

UPGRADE TO PREMIUM TO VIEW 13 MORE

TOTAL PAGES IN THIS WEBSITE

18

SOCIAL ENGAGEMENT



OTHER SITES

investor.alaskaair.com investor.alaskaair.com

Investors | Investors | Alaska Airlines

Skip to main content. Stock Quote and Chart. Annual Reports and Proxy. Annual Meeting and Proxy. Relax on a Beach. Board Room Airport Lounge. Earn and Use Miles. Buy and Share Miles. Profile and Tier Status. Stock quote and chart. Annual reports and proxy. Annual meeting and proxy. Alaska Receives DOJ Clearance. December 6, 2016. Alaska to acquire Virgin America. Alaska Acquires Virgin America Investor Deck. Alaska Air Group Reports December 2016 and Full-Year Operational Results. 160;  1.80.

investor.alderbio.com investor.alderbio.com

Our Mission - Alder Biopharmaceuticals

Annual Reports and Proxies. Annual Reports and Proxies. Alder is a clinical-stage biopharmaceutical company that discovers, develops, and seeks to commercialize therapeutic antibodies with the potential to transform current treatment paradigms in meaningful ways. The work being done at Alder today will potentially help those who suffer from migraine, autoimmune diseases, and inflammatory diseases. 2015 Alder Biopharmaceuticals Inc. Annual Reports and Proxies.

investor.alere.com investor.alere.com

Default Web Site Page

If you are the owner of this website, please contact your hosting provider: webmaster@investor.alere.com. It is possible you have reached this page because:. The IP address has changed. The IP address for this domain may have changed recently. Check your DNS settings to verify that the domain is set up correctly. It may take 8-24 hours for DNS changes to propagate. It may be possible to restore access to this site by following these instructions. For clearing your dns cache.

investor.aleris.com investor.aleris.com

Aleris - InvestorRoom - Aleris Overview

Aleris is a global leader in the production and sale of aluminum rolled products. From its headquarters in Cleveland, Ohio, Aleris operates 13 production facilities throughout the United States, Europe, and Asia, providing products and services to customers in a variety of industries. Mar 19, 2018. Aleris Reports Fourth Quarter and Full Year 2017 Results. Mar 14, 2018. Aleris to Announce Fourth Quarter and Full Year 2017 Financial Results on March 19. Mar 5, 2018. Monday, March 19, 2018. 1 216 910 3229.

investor.aligntech.com investor.aligntech.com

Align Technology, Inc. - Investors

Align Technology’s market opportunity and value proposition are strong and we are continuing to execute our strategies to increase adoption and utilization of our products and services worldwide. Stock Quote and Chart. View all ». Jan 30, 2018 at 4:30 PM ET. Fourth Quarter 2017 Financial Results Conference. View all ». Mar 6, 2018. Align Technology to Host Investor Day on May 23, 2018. Mar 5, 2018. Kevin J. Dallas Joins Align Technology Board of Directors. Feb 28, 2018. Feb 8, 2018. Feb 8, 2018.

investor.alimerasciences.com investor.alimerasciences.com

Investor Relations | Alimera Sciences

Skip to main navigation. Diabetic Macular Edema (DME). Retinal Vein Occlusion (RVO). Age-Related Macular Degeneration (AMD). Alimera Sciences’ primary focus is on ILUVIEN. Fluocinolone acetonide intravitreal implant) 0.19 mg. ILUVIEN is an intravitreal implant of fluocinolone acetonide and is the first DME treatment to deliver 36 months of continuous, low-dose corticosteroid therapy with a single injection. Feb 28, 2018. Alimera Sciences Reports Fourth Quarter and Full Year 2017 Financial Results. 2018 A...

investor.alkermes.com investor.alkermes.com

Alkermes PLC > Investor Relations > Corporate Overview

Message from the CEO. Q2 2015 Alkermes plc Earnings Conference Call. 160;at 8:30 am ET. 160; 0.54. Data as of 08/07/15 4:00 pm ET. Minimum 20 minute delay. Alkermes plc Reports Second Quarter 2015 Financial Results. Alkermes to Host Conference Call to Discuss Second Quarter 2015 Financial Results. Alkermes to Present Data From Late-Stage CNS Portfolio at Upcoming American Society of Clinical Psychopharmacology Annual Meeting. Goldman Sachs and Co. Jefferies and Co., Inc. JPMorgan Securities, Inc. Can I p...

investor.allegion.com investor.allegion.com

Allegion Investor Relations | Find Our Investor Services | Allegion

Safety and Security Institute. SEC and Financial Reports. Stock Quote and Chart. Sign Up for Allegion Updates. With a global network of pioneering, market-leading brands, proven operational excellence and financial performance, we expect Allegion to unlock inherent value for shareholders. See where Allegion has been and where it's growing. Take a look at our latest news and browse past company announcements. SEC and Financial Reports. Find ALLE's current stock price and compare that with market trends.

investor.allete.com investor.allete.com

Investors | ALLETE, Inc.

Skip to main navigation. Section 16 Insider Trades. ALLETE common stock trades on the New York Stock Exchange under the ticker symbol ALE, and has paid consecutive dividends since 1950. The company has been headquartered in Duluth, Minnesota since 1906. Mar 15, 2018. ALLETE Clean Energy to Build Montana Wind Energy Facility to Supply Electricity to NorthWestern Energy under Power Sale Agreement. Mar 1, 2018. ALLETE Clean Energy to Sell Phase II of Thunder Spirit Wind Farm to Montana-Dakota Utilities.

investor.alliancetrust.co.uk investor.alliancetrust.co.uk

www.alliancetrusts.com (JavaScript: Redirect)

investor.allscripts.com investor.allscripts.com

Allscripts - Investor Relations

Sunrise Clinical and Revenue Cycle. Wand for TouchWorks EHR. Products by Care Setting. Hospital and Health Systems. 2015 Allscripts Client Experience Financial Community Lunch and Q&A. Wednesday, August 5, 2015 . 12:00 pm ET  . Through Wednesday, August 5, 2015 . Click here for webcast. Click here to add this event to your calendar. 2015 Allscripts Client Experience Financial Community Lunch and Q&A. Q2 2015 Allscripts Healthcare Solutions, Inc. Earnings Conference Call. Tuesday, August 4, 2015 . Record ...